VERTEX PHARMACEUTICALS INC / MA Deferred Federal Income Tax Expense (Benefit)
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Deferred Federal Income Tax Expense (Benefit) of -$527.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for the quarter ending 2013-12-31 was -$127.60M.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for the quarter ending 2013-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for the quarter ending 2013-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for the quarter ending 2013-03-31 was $127.60M.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for fiscal 2025 was -$527.00M.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for fiscal 2024 was -$438.70M.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for fiscal 2023 was -$569.90M.
- VERTEX PHARMACEUTICALS INC / MA deferred federal income tax expense (benefit) for fiscal 2022 was -$404.00M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 12 month | Deferred Federal Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | -$527.00M 10-K · filed 2026-02-13 | ||||
| 2024-12-31 | -$438.70M 10-K · filed 2026-02-13 | ||||
| 2023-12-31 | -$569.90M 10-K · filed 2026-02-13 | ||||
| 2022-12-31 | -$404.00M 10-K · filed 2025-02-13 | ||||
| 2021-12-31 | -$36.90M 10-K · filed 2024-02-15 | ||||
| 2020-12-31 | $510.20M 10-K · filed 2023-02-10 | $510.22M 10-K · filed 2021-02-11 | |||
| 2019-12-31 | $184.30M 10-K · filed 2022-02-09 | $184.31M 10-K · filed 2020-02-13 | |||
| 2018-12-31 | -$1.11B 10-K · filed 2021-02-11 | ||||
| 2017-12-31 | -$113.81M 10-K · filed 2020-02-13 | ||||
| 2016-12-31 | $18.66M 10-K · filed 2019-02-13 | ||||
| 2015-12-31 | $497.00K 10-K · filed 2018-02-15 | ||||
| 2014-12-31 | $244.00K 10-K · filed 2017-02-23 | ||||
| 2013-12-31 | -$127.60M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$127.60M derived: sum of 2 quarters · filed 2016-02-16 | -$127.60M derived: sum of 3 quarters · filed 2016-02-16 | $0.00 10-K · filed 2016-02-16 | -$131.28M 10-K · filed 2014-02-11 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $0.00 derived: sum of 2 quarters · filed 2014-11-06 | $127.60M 10-Q · filed 2014-11-06 | ||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $127.60M 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | $127.60M 10-Q · filed 2014-05-05 | ||||
| 2012-12-31 | $0.00 10-K · filed 2015-02-13 | $31.31M 10-K · filed 2013-03-01 | |||
| 2011-12-31 | $19.63M 10-K · filed 2014-02-11 | ||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |